Page 2 - Nasdaq Rlmd News Today

Shares of Relmada Therapeutics, Inc. (NASDAQ:RLMD – Get Free Report) have been assigned a consensus recommendation of “Moderate Buy” from the four brokerages that are presently covering the company, MarketBeat Ratings reports. Two investment analysts have rated the stock with a hold recommendation and two have assigned a buy recommendation to the company. The average […]

Relmada Therapeutics, Inc. (NASDAQ:RLMD – Get Free Report) has received a consensus rating of “Hold” from the six analysts that are covering the company, MarketBeat reports. Four research analysts have rated the stock with a hold rating and two have issued a buy rating on the company. The average 12 month price objective among brokers […]

Relmada Therapeutics, Inc. (NASDAQ:RLMD – Get Free Report) was the recipient of a significant decline in short interest in August. As of August 15th, there was short interest totalling 689,800 shares, a decline of 18.8% from the July 31st total of 849,900 shares. Based on an average daily trading volume, of 169,700 shares, the short-interest […]

Shares of Relmada Therapeutics, Inc. (NASDAQ:RLMD – Get Free Report) have been assigned a consensus recommendation of “Hold” from the six analysts that are presently covering the firm, MarketBeat Ratings reports. Four investment analysts have rated the stock with a hold recommendation and two have assigned a buy recommendation to the company. The average twelve-month […]

Tiedemann Advisors LLC boosted its holdings in Relmada Therapeutics, Inc. (NASDAQ:RLMD – Get Rating) by 97.9% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 20,215 shares of the company’s stock after buying an additional 10,000 shares during the quarter. […]

The Manufacturers Life Insurance Company lowered its position in Relmada Therapeutics, Inc. (NASDAQ:RLMD – Get Rating) by 17.7% in the 4th quarter, HoldingsChannel reports. The institutional investor owned 25,037 shares of the company’s stock after selling 5,393 shares during the quarter. The Manufacturers Life Insurance Company’s holdings in Relmada Therapeutics were worth $89,000 at the […]

Shares of Relmada Therapeutics, Inc. (NASDAQ:RLMD – Get Rating) have earned an average rating of “Hold” from the seven ratings firms that are currently covering the firm, Marketbeat reports. Three research analysts have rated the stock with a hold recommendation and two have issued a buy recommendation on the company. The average twelve-month price target […]

Shares of Relmada Therapeutics, Inc. (NASDAQ:RLMD – Get Rating) have received an average recommendation of “Hold” from the seven ratings firms that are currently covering the stock, Marketbeat Ratings reports. Three equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company. The average 12-month […]

Apricus wealth LLC lowered its stake in shares of Relmada Therapeutics, Inc. (NASDAQ:RLMD – Get Rating) by 28.0% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 77,329 shares of the company’s stock after selling 30,000 shares during the quarter. apricus wealth LLC owned approximately […]

Relmada Therapeutics (NASDAQ:RLMD – Get Rating) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research note issued on Wednesday, Zacks.com reports. According to Zacks, “Relmada Therapeutics Inc. is a clinical stage, public specialty pharmaceutical company. The Company is developing LevoCap ER, an abuse resistant, once-a-day sustained release […]